Suppr超能文献

磷脂酰肌醇-3激酶δ与原发性免疫缺陷

PI3Kδ and primary immunodeficiencies.

作者信息

Lucas Carrie L, Chandra Anita, Nejentsev Sergey, Condliffe Alison M, Okkenhaug Klaus

机构信息

Molecular Development of the Immune System Section, Laboratory of Immunology, and Clinical Genomics Program, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA.

Immunobiology Department, Yale University School of Medicine, New Haven, Connecticut 06511, USA.

出版信息

Nat Rev Immunol. 2016 Nov;16(11):702-714. doi: 10.1038/nri.2016.93. Epub 2016 Sep 12.

Abstract

Primary immunodeficiencies are inherited disorders of the immune system, often caused by the mutation of genes required for lymphocyte development and activation. Recently, several studies have identified gain-of-function mutations in the phosphoinositide 3-kinase (PI3K) genes PIK3CD (which encodes p110δ) and PIK3R1 (which encodes p85α) that cause a combined immunodeficiency syndrome, referred to as activated PI3Kδ syndrome (APDS; also known as p110δ-activating mutation causing senescent T cells, lymphadenopathy and immunodeficiency (PASLI)). Paradoxically, both loss-of-function and gain-of-function mutations that affect these genes lead to immunosuppression, albeit via different mechanisms. Here, we review the roles of PI3Kδ in adaptive immunity, describe the clinical manifestations and mechanisms of disease in APDS and highlight new insights into PI3Kδ gleaned from these patients, as well as implications of these findings for clinical therapy.

摘要

原发性免疫缺陷是免疫系统的遗传性疾病,通常由淋巴细胞发育和激活所需基因的突变引起。最近,几项研究在磷酸肌醇3激酶(PI3K)基因PIK3CD(编码p110δ)和PI3R1(编码p85α)中鉴定出功能获得性突变,这些突变会导致一种联合免疫缺陷综合征,称为活化PI3Kδ综合征(APDS;也称为导致衰老T细胞、淋巴结病和免疫缺陷的p110δ激活突变(PASLI))。矛盾的是,影响这些基因的功能丧失和功能获得性突变都会导致免疫抑制,尽管其机制不同。在这里,我们综述了PI3Kδ在适应性免疫中的作用,描述了APDS的临床表现和疾病机制,并强调了从这些患者身上获得的关于PI3Kδ的新见解,以及这些发现对临床治疗的意义。

相似文献

1
PI3Kδ and primary immunodeficiencies.
Nat Rev Immunol. 2016 Nov;16(11):702-714. doi: 10.1038/nri.2016.93. Epub 2016 Sep 12.
2
The Treatment of Activated PI3Kδ Syndrome.
Front Immunol. 2018 Sep 7;9:2043. doi: 10.3389/fimmu.2018.02043. eCollection 2018.
3
Activated PI3 Kinase Delta Syndrome: From Genetics to Therapy.
Front Immunol. 2018 Feb 27;9:369. doi: 10.3389/fimmu.2018.00369. eCollection 2018.
4
Respiratory Manifestations of the Activated Phosphoinositide 3-Kinase Delta Syndrome.
Front Immunol. 2018 Mar 5;9:338. doi: 10.3389/fimmu.2018.00338. eCollection 2018.
5
PI3K pathway defects leading to immunodeficiency and immune dysregulation.
J Allergy Clin Immunol. 2019 May;143(5):1676-1687. doi: 10.1016/j.jaci.2019.03.017.
6
Conformational disruption of PI3Kδ regulation by immunodeficiency mutations in and .
Proc Natl Acad Sci U S A. 2017 Feb 21;114(8):1982-1987. doi: 10.1073/pnas.1617244114. Epub 2017 Feb 6.
7
Homeostatic and pathogenic roles of PI3Kδ in the human immune system.
Adv Immunol. 2020;146:109-137. doi: 10.1016/bs.ai.2020.02.001. Epub 2020 Mar 19.

引用本文的文献

1
Eukaryotic initiation factors: central factor associating mRNA translational plasticity during neuropathic pain progression.
Front Neurol. 2025 Jul 30;16:1566205. doi: 10.3389/fneur.2025.1566205. eCollection 2025.
4
Genomics reveals eleven obesity endotypes with distinct biological and phenotypic signatures.
medRxiv. 2025 Jul 2:2025.06.30.25330607. doi: 10.1101/2025.06.30.25330607.
5
Activated phosphoinositide 3-kinase delta syndrome: Pathogenesis, clinical manifestations, and treatment.
Pediatr Discov. 2024 Aug 23;2(3):e2504. doi: 10.1002/pdi3.2504. eCollection 2024 Sep.
6
Refractory marginal zone lymphoma uncovers activated phosphoinositide 3-kinase delta syndrome type 1 (APDS1).
J Allergy Clin Immunol Glob. 2025 May 26;4(3):100503. doi: 10.1016/j.jacig.2025.100503. eCollection 2025 Aug.
9
Unveiling fatty acid subtypes: immunometabolic interplay and therapeutic opportunities in gastric cancer.
Front Oncol. 2025 May 26;15:1570873. doi: 10.3389/fonc.2025.1570873. eCollection 2025.
10
PI3Kδ as a Novel Therapeutic Target for Aggressive Prostate Cancer.
Cancers (Basel). 2025 May 9;17(10):1610. doi: 10.3390/cancers17101610.

本文引用的文献

1
Precision treatment with sirolimus in a case of activated phosphoinositide 3-kinase δ syndrome.
Clin Immunol. 2016 Oct;171:38-40. doi: 10.1016/j.clim.2016.07.017. Epub 2016 Jul 19.
2
Phosphatase and tensin homolog (PTEN) mutation can cause activated phosphatidylinositol 3-kinase δ syndrome-like immunodeficiency.
J Allergy Clin Immunol. 2016 Dec;138(6):1672-1680.e10. doi: 10.1016/j.jaci.2016.03.055. Epub 2016 Jul 14.
3
Clinical and immunologic phenotype associated with activated phosphoinositide 3-kinase δ syndrome 2: A cohort study.
J Allergy Clin Immunol. 2016 Jul;138(1):210-218.e9. doi: 10.1016/j.jaci.2016.03.022. Epub 2016 Apr 21.
4
Activated PI3Kδ syndrome type 2: Two patients, a novel mutation, and review of the literature.
Pediatr Allergy Immunol. 2016 Sep;27(6):640-4. doi: 10.1111/pai.12585. Epub 2016 May 27.
5
Dominant Splice Site Mutations in PIK3R1 Cause Hyper IgM Syndrome, Lymphadenopathy and Short Stature.
J Clin Immunol. 2016 Jul;36(5):462-71. doi: 10.1007/s10875-016-0281-6. Epub 2016 Apr 13.
6
PTEN opposes negative selection and enables oncogenic transformation of pre-B cells.
Nat Med. 2016 Apr;22(4):379-87. doi: 10.1038/nm.4062. Epub 2016 Mar 14.
10
Molecules in medicine mini-review: isoforms of PI3K in biology and disease.
J Mol Med (Berl). 2016 Jan;94(1):5-11. doi: 10.1007/s00109-015-1352-5. Epub 2015 Dec 10.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验